A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-06-30
Adverse events
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-08-31 (study day 44); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-09-22 (study day 66); relationship: not assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-10-27 (study day 101); relationship: not assessed; serious criteria: hospitalization
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-30 (study day 165); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-02-20 (study day 217); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-09 (study day 235); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-04-01 (study day 258); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-05-30 (study day 317); relationship: N
Data queries
No data queries.